Evolus (EOLS) Stock Price, News & Analysis

Company Overview

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Key Stats

• Today's Range: $12.53 to $12.81
• 50-Day Range: $11.88 to $17.49
• 52-Week Range: $9.29 to $17.82
• Volume: 104,254 shs
• Average Volume: 591,425 shs
• Market Capitalization: $801.63 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.00
• Consensus Rating: Buy

Evolus Stock Analysis - MarketRank™

Evolus scored higher than 81% of companies evaluated by MarketBeat, and ranked 226th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Evolus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Evolus has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Evolus are expected to grow in the coming year, from ($0.63) to ($0.07) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Evolus is -13.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Evolus is -13.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Evolus has a P/B Ratio of 140.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.58% of the outstanding shares of Evolus have been sold short.

Short Interest Ratio / Days to Cover

Evolus has a short interest ratio ("days to cover") of 8.9.

Change versus previous month

Short interest in Evolus has recently increased by 8.82%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Evolus does not currently pay a dividend.

Dividend Growth

Evolus does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.5 / 5
• Environmental Score: -1.27

Percentage of Shares Shorted

8.58% of the outstanding shares of Evolus have been sold short.

Short Interest Ratio / Days to Cover

Evolus has a short interest ratio ("days to cover") of 8.9.

Change versus previous month

Short interest in Evolus has recently increased by 8.82%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.32

News Sentiment

Evolus has a news sentiment score of 1.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Evolus this week, compared to 4 articles on an average week.

Search Interest

4 people have searched for EOLS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Evolus to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Evolus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $138,326.00 in company stock.

Percentage Held by Insiders

Only 6.10% of the stock of Evolus is held by insiders.

Percentage Held by Institutions

90.69% of the stock of Evolus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

EOLS Stock Analysis - Frequently Asked Questions

How have EOLS shares performed this year?

Evolus' stock was trading at $10.53 at the start of the year. Since then, EOLS stock has increased by 19.9% and is now trading at $12.63.
View the best growth stocks for 2024 here.

How were Evolus' earnings last quarter?

Evolus, Inc. (NASDAQ:EOLS) posted its quarterly earnings results on Tuesday, March, 23rd. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.18. The business had revenue of $20.58 million for the quarter, compared to the consensus estimate of $20.60 million. Evolus had a negative net margin of 22.33% and a negative trailing twelve-month return on equity of 847.60%.
Read the conference call transcript.

When did Evolus IPO?

Evolus (EOLS) raised $65 million in an initial public offering (IPO) on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

Who are Evolus' major shareholders?

Top institutional shareholders of Evolus include Caligan Partners LP (3.46%), Stonepine Capital Management LLC (2.16%), State Street Corp (2.02%) and Geode Capital Management LLC (1.91%). Insiders that own company stock include Alphaeon 1 Llc, Medytox Inc, David Moatazedi, Rui Avelar, Vikram Malik, Sandra Beaver, Lauren P Silvernail, Tomoko Yamagishi-Dressler, David N Gill, Robert Hayman and Crystal Muilenburg.
View institutional ownership trends.

How do I buy shares of Evolus?

Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Evolus own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Evolus investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY).

Company Calendar

• Last Earnings: 3/23/2021
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/06/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EOLS
• CUSIP: N/A
• CIK: 1570562
• Web: www.evolus.com
• Phone: (949) 284-4555
• Fax: N/A
• Employees: 170
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $23.00
• High Stock Price Target: $27.00
• Low Stock Price Target: $20.00
• Potential Upside/Downside: +82.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-61,690,000.00
• Net Margins: -22.33%
• Pretax Margin: -22.20%
• Return on Equity: -847.60%
• Return on Assets: -22.15%

Debt

• Debt-to-Equity Ratio: 20.58
• Current Ratio: 2.47
• Quick Ratio: 2.23

Sales & Book Value

• Annual Sales: $202.09 million
• Price / Sales: 3.96
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.36) per share
• Price / Book: -35.08

Miscellaneous

• Outstanding Shares: 63,320,000
• Free Float: 59,458,000
• Market Cap: $799.73 million
• Optionable: Optionable
• Beta: 1.31